Suraksha Diagnostic Ltd
Suraksha Diagnostic Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. - Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. - Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. - Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. - Business model's strong B2C focus (>93% revenue) supports sustainable margins. - Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. - CAPEX planned at around Rs.
From Suraksha Diagnostic Ltd's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Expected revenue growth for FY '26 is around 18%-20% compared to FY '25.
- Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25.
- Price increases are planned at around 2%-3% every alternate year.
- Market share impact from new competitors entering Eastern India has not been seen yet.
- Opening 15-18 new centers in FY '26, including 8 centers in the first quarter itself, supports growth.
- Expansion plans focused on Eastern India with potential acquisitions if suitable.
- Growth also driven by new services such as genomic and fetal medicine tests, expected to scale over 2-3 years.
- Mature centers expected to deliver margin expansion due to operating leverage, supporting profitable growth.
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned CAPEX for FY '26 is around Rs. 70 crore (Ritu Mittal).
- CAPEX mainly for opening new centers: 4 big centers (~Rs. 10 Cr each) and 4 small centers (Rs. 1.5-2 Cr each).
- Additional CAPEX may depend on PPP centers, but exact numbers unknown due to tender-based process.
- Strategic investment includes establishment of MRI at Calcutta Medical College within 90 days.
- Investment to build genomic lab, expected to launch soon, enhancing B2B business.
- Focus on expanding the network with 15-18 new centers planned in FY '26.
- Potential acquisitions in Eastern India considered if they fit quality and price criteria.
- Emphasis on technology enhancement and operational efficiency as part of future growth.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company does not provide a specific order book or pending orders figure for PPP (Public-Private Partnership) centers as these are awarded through a tendering process and are uncertain.
- They are in the process of establishing an MRI center in Calcutta Medical College within the next 90 days, noted as a significant opportunity.
- For the fiscal year 2026, Suraksha plans to add approximately 15-18 new centers.
- In the first quarter of FY '26, they have already opened 5 centers and plan to open 3 more shortly, totaling 8 centers.
- The company has secured necessary approvals for the majority of proposed centers, indicating a robust pipeline for center openings.
- They continue to focus on organic growth primarily in Eastern India with potential for acquisitions if suitable.
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagnostic Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby Ltd (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Narayana Hrudayalaya Ltd (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
- Healthcare Global Enterprises Ltd (Q4 FY25)
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. Key concall takeaways from Healthcare Global Enterprises Ltd's Q4 FY25…
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q4 FY25 results?
Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. - Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. - Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. - Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. - Business model's strong B2C focus (>93% revenue) supports sustainable margins. - Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. - CAPEX planned at around Rs.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Planned CAPEX for FY '26 is around Rs.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.